Early or Wait? The BPH Timing Debate I Watched at AUA 2026

A field note from a session where reasonable urologists disagreed, on purpose.

One of the liveliest sessions I sat in on at AUA 2026 was a genuine debate: for a man with bothersome but not dangerous BPH symptoms, should you intervene early and electively, or hold steady and act only when something triggers the need? As many of you know, I am not a urologist. I am here representing proudP, and I was in the audience taking notes. So this is a high-level account of what I captured, not a clinical position, and I have surely missed nuance. I am not here to pick a side, and neither was the session in the end.

The organizers anchored it on one deliberately ambiguous patient: a 62-year-old man, several years of moderate symptoms, already on an alpha-blocker, sexually active and concerned about preserving ejaculation, on anticoagulation, with a notably large prostate and a rising post-void residual. The kind of patient where you can poll a room of experts and get a genuine split. Then they argued it out: Dean Elterman, MD and Sijo Parekattil, MD made the case for early intervention, Charles Welliver, MD made the case for waiting, and Daniel Kellner, MD framed the index case and the balanced view, moderated by Bilal Chughtai, MD.

The case for early, elective intervention

Dr. Elterman and Dr. Parekattil made the case here. One camp made a pointed argument that watchful waiting is not a neutral act. They walked through the measurable costs that can accumulate during untreated years: disrupted sleep, mood and quality-of-life effects, sexual and occupational impact, and fall risk in older men. They raised the long-term tradeoffs of staying on daily medication. And they argued that minimally invasive therapies have matured to the point where they can reasonably be offered as a first-line choice rather than only as an escalation, pointing to recent trial data and to patient-preference research showing many men prioritize preserving ejaculation and prefer a one-time procedure when options are comparable. Dr. Elterman went further, introducing a name for treating in this window, framing it as First-line Interventional Therapy (FIT) rather than a step up the ladder. 

The case for a triggered, watchful approach

Dr. Welliver made the case here. The other camp pushed back just as firmly, and their central point was necessity, not just timing. They cited cohort data showing that only a small share of men who start medication go on to a procedure within five years, meaning most men never needed one in that window. They argued that the bladder-health rationale for early action, while plausible, rests largely on inferential data, that the timeline from safe to unsafe is not well defined, and that a hypothetical should not become the sole justification for a procedure. And they made the fair point that minimally invasive does not mean risk-free: complications happen, recovery is real, and a procedure does not guarantee no further treatment.

Interestingly, one slide cut against the wait camp from inside their own argument, suggesting that when medical therapy is prolonged too long, some men reach surgery later, older, and with more comorbidity, in a worse window for good outcomes. That tension, that waiting has costs too, is exactly why the debate does not resolve cleanly.

Where it landed: shared decision-making with patient-matched triggers

Dr. Kellner, who presented the anchoring case, framed the resolution. What I appreciated is that the session did not crown a winner. It resolved into shared decision-making, matched to the individual patient.

The early, elective path tends to fit a healthier man who wants off daily medication, accepts the possibility of sexual side effects, and wants to avoid downstream complications. The triggered, watchful path tends to fit a man with higher surgical risk, a strong priority on preserving sexual function, mild and tolerable symptoms, anticoagulation, or an unclear diagnosis, who then acts on a relative trigger: medication intolerance or failure, rapid progression, high-risk bladder changes, or a large prostate with a rising post-void residual.

The index patient sat right in that tension. His large gland and rising residual pulled toward acting; his anticoagulation and ejaculatory-preservation concerns pulled toward waiting. There was no single right answer, only the right conversation.

What makes that conversation work

Here is the part that stayed with me, and it is true for either camp. A shared decision is only as good as the information it rests on. Whether a clinician leans early or triggered, the decision and the follow-up both depend on objective signal over time: is this man stable, or is he trending the wrong way? A single office snapshot rarely answers that. A trend does.

That is where proudP fits, and it fits both sides equally. proudP gives clinicians and patients an objective, at-home uroflowmetry measurement alongside IPSS scores and a bladder diary, building a trend rather than a snapshot. For the clinician leaning triggered, that is how you actually see a trigger arrive instead of guessing. For the clinician leaning early, it is how you document the baseline and the result. Either way, it turns the timing conversation into a data-driven one rather than an impression.

See how proudP supports objective flow tracking for shared decision-making.

I would welcome corrections from those of you who argue this for a living. The cases and data belong to the panelists. The thing I took away is simpler than the debate: wherever you land, land there with the patient, and land there on data.

---

Frequently asked questions

Should men with BPH be treated early or should they wait? 

There is genuine disagreement. One view holds that untreated symptoms carry accumulating costs and that minimally invasive options are now good enough to offer early. Another holds that most men never need a procedure and that waiting for a clear trigger is reasonable. Most experts resolve it through shared decision-making matched to the individual patient.

What is a triggered approach to BPH? 

Intervening only when a clear trigger appears, such as medication intolerance or failure, rapid symptom progression, high-risk bladder changes, or a large prostate with a rising post-void residual, rather than electively early.

Why does objective tracking matter in this decision?

Because the choice and the follow-up both depend on whether a patient is stable or trending worse over time, which a single visit rarely shows. A trend in objective measures like urine flow helps make the timing conversation data-driven.